肝胆相照论坛

标题: 吉利德的乙型肝炎药物在2018年销售令人失望 [打印本页]

作者: StephenW 时间: 2019-2-12 10:10 标题: 吉利德的乙型肝炎药物在2018年销售令人失望

HOME Pharma
Gilead’s hepatitis B drug posts disappointing sales in 2018

By Kim Yun-mi
Published 2019.02.11 15:29
Updated 2019.02.11 15:29
comments 0

Gilead Sciences Korea’s hepatitis B treatment Vemlidy (ingredient: tenofovir ala fenamide, TAF) failed to achieve rapid sales growth last year. The drug made the market debut in late 2017 drawing the industry’s attention because of its improved renal and bone safety.
Gilead Sciences Korea’s hepatitis B treatment Vemlidy (left) and Ildong Pharmaceutical’s Besivo

Vemlidy, which changed the base of Viread (tenofovir disoproxil fumarate, TDF), recorded less than 3.5 billion won ($3.1 million) worth of outpatient prescriptions last year. Besivo (besifovir dipivoxil maleate), Korea’s 28th novel drug and Ildong Pharmaceutical’s first self-developed medicine, also sold less than 300 million won.

To sum up, new hepatitis B treatments have failed to outrival conventional drugs last year.

According to UBIST data for the past two years, Gilead’s Vemlidy marked 3.49 billion won outpatient prescriptions in 2018.

Gilead won the license for Vemlidy in May 2017 and insurance coverage for the drug in November 2017. Patients who receive Vemlidy as the first treatment for hepatitis B and those resistant to existing treatments can benefit from insurance coverage when using Vemlidy.

Gilead emphasized that Vemlidy had stronger renal and bone safety and less drug tolerance risk compared to Viread, expecting not only Viread takers would switch to Vemlidy, but patients with renal and bone problems would take the new drug. However, limitations in the reimbursement dented Vemlidy sales.

The authorities give the insurance benefit to alternative hepatitis B treatments in the case of drug tolerance, insufficient or no response to the drug, pregnancy, and severe side effects that are objectively proven.

They also allow the insurance benefit partially for medical reasons such as the need for improvement of medication compliance and the improvement of cost-effectiveness.

Some physicians report reimbursement cuts after a switch to Vemlidy for patients with renal or bone diseases to the Korean Association for the Study of the Liver. However, the association said it was too early to raise its voice against reimbursement reductions.

Ildong’s Besivo, the locally developed new drug, sold 284 million won in 2018, failing to carve out a share out of the over 200 billion won worth local hepatitis B treatment market.

Compared to conventional hepatitis B drugs, Besivo is at a disadvantage in insurance coverage. The authorities ban the use of Besivo in patients with a glomerular filtration rate of less than 50. Plus, physicians should administrate Besivo with 660mg of L-carnitine, which is another demerit.

Hepatitis B drug industry leader Viread posted 153.6 billion won in outpatient prescriptions last year, down 7.4 percent from a year earlier.

Despite the sales decline since the rollouts of generic drugs in late 2017, Viread still kept its stable status as a blockbuster treatment with over 150 billion won sales.

Generic copies of Viread did not show impressive results. Chong Kun Dang’s Tenofobell sold 1.4 billion won, Dong-A ST’s Virreal, 1.3 billion won, Jeil Pharm’s Tecavir, 927 million won, and Hanmi Pharmaceutical’s Tefovir, 955 million won.

BMS Pharmaceutical Korea’s Baraclude (entecavir) recorded 72.3 billion won prescriptions last year, with its pace of sales decline slowing compared to 2015 or 2016 when it had to compete against new generics.

[email protected]

<© Korea Biomedical Review, All rights reserved.>

作者: StephenW 时间: 2019-2-12 10:10

HOME Pharma
吉利德的乙型肝炎药物在2018年销售令人失望

金云英
发表于2019.02.11 15:29
更新日期2019.02.11 15:29
评论0

Gilead Sciences韩国的乙型肝炎治疗Vemlidy（成分：tenofovir ala fenamide，TAF）去年未能实现快速的销售增长。该药物于2017年底在市场上首次亮相，因其改善了肾脏和骨骼的安全性而引起了业界的关注。
Gilead Sciences韩国乙肝治疗Vemlidy（左）和Ildong Pharmaceutical's Besivo

Vemlidy改变了Viread（替诺福韦地索普西富马酸盐，TDF）的基础，去年录得不到35亿韩元（310万美元）的门诊处方。 Besivo（besifovir dipivoxil maleate），韩国第28种新药和Ildong Pharmaceutical的第一种自主研发药物，也销售不到3亿韩元。

总之，去年新的乙型肝炎治疗未能超过常规药物。

根据UBIST过去两年的数据，吉利德的Vemlidy在2018年标记了34.9亿韩元的门诊处方。

Gilead于2017年5月获得了Vemlidy的许可，并于2017年11月获得了该药的保险。在使用Vemlidy时，接受Vemlidy作为乙型肝炎的首次治疗和对现有治疗有抵抗力的患者可享受保险。

Gilead强调，与Viread相比，Vemlidy具有更强的肾脏和骨骼安全性以及更低的药物耐受性风险，预计不仅Viread接受者将转向Vemlidy，但患有肾脏和骨骼问题的患者将服用新药。然而，报销的限制削弱了Vemlidy的销售额。

在药物耐受，药物不足或没有反应，怀孕和客观证实的严重副作用的情况下，当局给予替代乙型肝炎治疗保险福利。

他们还允许保险福利部分用于医疗原因，例如需要改善药物依从性和提高成本效益。

一些医生报告称，在向韩国肝脏研究协会转交给Vemlidy患有肾脏或骨骼疾病的患者后，可以减少报销费用。不过，该协会表示现在提出反对报销削减的声音还为时过早。

Ildong的Besivo是当地开发的新药，2018年售出2.84亿韩元，未能从超过2000亿韩元的当地乙型肝炎治疗市场中分得一杯羹。

与传统的乙型肝炎药物相比，贝西沃在保险方面处于劣势。当局禁止在肾小球滤过率低于50的患者中使用Besivo。此外，医生应该给予Besivo 660mg左旋肉碱，这是另一个缺点。

去年，乙型肝炎药物行业的领导者Viread在门诊处方上发布了1536亿韩元，比去年同期下降了7.4％。

尽管自2017年末推出仿制药以来销量下滑，但Viread仍然保持其稳定的地位，成为销量超过1500亿韩元的重磅油炸弹。

Viread的通用副本没有显示出令人印象深刻的结果。 Chong Kun Dang的Tenofobell售出14亿韩元，Dong-A ST的Virreal，13亿韩元，Jeil Pharm的Tecavir，9.27亿韩元，以及Hanmi Pharmaceutical的Tefovir，9.55亿韩元。

BMS Pharmaceutical Korea的Baraclude（恩替卡韦）去年录得723亿韩元的处方药，其销售速度与2015年或2016年相比有所下降，当时它不得不与新的仿制药竞争。

[email protected]

<©Korea Biomedical Review，保留所有权利。>

作者: newchinabok 时间: 2019-2-12 10:34

吃老本，快吃完了

作者: 齐欢畅 时间: 2019-2-12 21:44

降价吧

作者: Hepbest 时间: 2019-2-13 09:52

销售业绩不好，说明战友不买账。
倒逼着这帮人研发HBV的The Terminator ，治愈药啦。
否则战友还是不能买账

作者: newchinabok 时间: 2019-2-13 11:48

Hepbest 发表于 2019-2-13 09:52
销售业绩不好，说明战友不买账。
倒逼着这帮人研发HBV的The Terminator ，治愈药啦。
否则战友还是不能买账 ...

吉利德就是个投资公司，根本没有研发人员和新药储备，关门是迟早的事。

作者: ivanich 时间: 2019-2-14 14:25

应该说恩替已经能解决大部分问题而且相对很便宜！吉利德在hbv功能性治愈方面没什么建树，前景不妙

作者: 左罗 时间: 2019-2-14 14:47

Hepbest 发表于 2019-2-13 09:52
销售业绩不好，说明战友不买账。
倒逼着这帮人研发HBV的The Terminator ，治愈药啦。
否则战友还是不能买账 ...

市场倒逼这是好事啊，但愿能逼出像丙干那样的乙肝治愈药出来那就太好了哈！

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)